Lixte Biotechnology Holdings Inc Aktie News

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Response with LIXTE's Proprietary Compound LB100

New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.

PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors for the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock and Common Warra...

PASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement with accredited investors on the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Converti...

Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE's Ongoing Clinical Trials for Ovarian and Colorectal Cancers

-Started Two New Clinical Trials,  Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-

-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE's LB-100  in Combination with GSK's Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has added the Robert H. Lurie Comprehensive Cancer Center (Luri...